In the present analysis we aimed to 1) describe treatment utilisation and patient characteristics of sulfonylurea (SU) and insulin vs. incretin-based treatment in a real world setting, 2) identify patients with stable treatment throughout a two year follow-up, and 3) to compare blood glucose control, body weight, rates of hypoglycaemia and incident co-morbidity/vascular events among the different treatment strategies in those with stable drug treatment. Here, INS is linked to Hypoglycemia.